share_log

Panbela Therapeutics | 424B3: Prospectus

SEC announcement ·  Aug 14 12:43
Summary by Moomoo AI
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the previously dated prospectus from April 2, 2024, with details from their quarterly report. This supplement relates to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, must be read in conjunction with the Prospectus, and in case of any inconsistency, the information in the supplement prevails. The Quarterly Report details the company's financial...Show More
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the previously dated prospectus from April 2, 2024, with details from their quarterly report. This supplement relates to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, must be read in conjunction with the Prospectus, and in case of any inconsistency, the information in the supplement prevails. The Quarterly Report details the company's financial status, including a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash from $2.578 million to $59,000. The report also mentions the risks involved in investing in the company's securities and states that the SEC has not approved or disapproved the accuracy or adequacy of the prospectus supplement or the Prospectus.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more